Rare codons capacitate Kras-driven de novo tumorigenesis

Journal of Clinical Investigation

Volumn 125, Issue 1, 2015, Pages 222-233

  Pershing, Nicole L K ^a   Lampson, Benjamin L ^a,b   Belsky, Jason A ^a   Kaltenbrun, Erin ^a   MacAlpine, David M ^a   Counter, Christopher M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAS PROTEIN; CODON; KRAS2 PROTEIN, MOUSE; PROTEIN P21; URETHAN;

ALLELE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CODON; CODON USAGE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENOTYPE; HUMAN; HUMAN CELL; KRAS GENE; MOUSE; MOUSE EMBRYO; MUTATION; NONHUMAN; ONCOGENE RAS; PHENOTYPE; PROTEIN EXPRESSION; PROTO ONCOGENE; REDUCTION; TRANSGENIC MOUSE; 129 MOUSE; ADENOMA; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; CHEMICALLY INDUCED; FEMALE; GENETICS; LUNG TUMOR; MALE; PATHOLOGY; TUMOR VOLUME;

ADENOMA; ANIMALS; CARCINOGENESIS; CELL PROLIFERATION; CELLS, CULTURED; CODON; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS P21(RAS); TUMOR BURDEN; URETHANE;

EID: 84920450418     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI77627     Document Type: Article

References (53)

1. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11(11):761-774.
2. Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging Ras back in the ring. Cancer Cell. 2014;25(3):272-281.
3. Ahearn IM, Haigis K, Bar-Sagi D, Philips MR. Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol. 2012;13(1):39-51.
4. Lampson BL, et al. Rare codons regulate KRas oncogenesis. Curr Biol. 2013;23(1):70-75.
5. Plotkin JB, Kudla G. Synonymous but not the same: the causes and consequences of codon bias. Nat Rev Genet. 2011;12(1):32-42.
6. Nakamura Y, Gojobori T, Ikemura T. Codon usage tabulated from international DNA sequence databases: status for the year 2000. Nucleic Acids Res. 2000;28(1):292.
7. Zolotukhin S, Potter M, Hauswirth WW, Guy J, Muzyczka N. A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol. 1996;70(7):4646-4654.
8. Hense W, et al. Experimentally increased codon bias in the Drosophila Adh gene leads to an increase in larval, but not adult, alcohol dehydro-genase activity. Genetics. 2010;184(2):547-555.
9. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer. 2010;10(1):51-57.
10. Sarkisian CJ, et al. Dose-dependent onco-gene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol. 2007;9(5):493-505.
11. Supek F, Miñana B, Valcárcel J, Gabaldón T, Ben Lehner. Synonymous mutations frequently act as driver mutations in human cancers. Cell. 2014;156(6):1324-1335.
12. To MD, et al. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat Genet. 2008;40(10):1240-1244.
13. Dassano A, et al. Mouse pulmonary adenoma susceptibility 1 locus is an expression QTL modulating Kras-4A. PLoS Genet. 2014;10(4):e1004307.
14. Ichise T, Yoshida N, Ichise H. H-, N-and Kras cooperatively regulate lymphatic vessel growth by modulating VEGFR3 expression in lymphatic endothelial cells in mice. Development. 2010;137(6):1003-1013.
15. Horio Y, et al. Ki-ras and p53 mutations are early and late events, respectively, in urethane-in-duced pulmonary carcinogenesis in A/J mice. Mol Carcinog. 1996;17(4):217-223.
16. Dwyer-Nield LD, et al. Epistatic interactions govern chemically-induced lung tumor susceptibility and Kras mutation site in murine C57BL/6J-ChrA/J chromosome substitution strains. Int J Cancer. 2010;126(1):125-132.
17. DeNicola GM, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011;475(7354):106-109.
18. Zhang Z, et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet. 2001;29(1):25-33.
19. To MD, et al. A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nat Genet. 2006;38(8):926-930.
20. Jackson EL, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15(24):3243-3248.
21. Cazorla M, et al. Ki-ras gene mutations and absence of p53 gene mutations in spontaneous and urethane-induced early lung lesions in CBA/J mice. Mol Carcinog. 1998;21(4):251-260.
22. Malkinson AM. The genetic basis of susceptibility to lung tumors in mice. Toxicology. 1989;54(3):241-271.
23. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997;88(5):593-602.
24. Buhrman G, Wink G, Mattos C. Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf. Structure. 2007;15(12):1618-1629.
25. Buhrman G, Holzapfel G, Fetics S, Mattos C. Allosteric modulation of Ras positions Q61 for a direct role in catalysis. Proc Natl Acad Sci U S A. 2010;107(11):4931-4936.
26. Scheffzek K, et al. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science. 1997;277(5324):333-338.
27. Collado M, et al. Tumour biology: Senescence in premalignant tumours. Nat Cell Biol. 2005;436(7051):642-642.
28. Serrano M, et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996;85(1):27-37.
29. Sharpless NE, et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigene-sis. Nature. 2001;413(6851):86-91.
30. Busch SE, et al. ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma. Oncogene. 2014;33(20):2665-2673.
31. Fisher GH, et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 2001;15(24):3249-3262.
32. Kimchi-Sarfaty C, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315(5811):525-528.
33. Robinson F, Jackson RJ, Smith CWJ. Expression of human nPTB is limited by extreme suboptimal codon content. PLoS One. 2008;3(3):e1801.
34. Zhang F, Saha S, Shabalina SA, Kashina A. Differential arginylation of actin isoforms is regulated by coding sequence-dependent degradation. Science. 2010;329(5998):1534-1537.
35. Jacobo SMP, DeAngelis MM, Kim IK, Kazlauskas A. Age-related macular degeneration-associated silent polymorphisms in HtrA1 impair its ability to antagonize insulin-like growth factor 1. Mol Cell Biol. 2013;33(10):1976-1990.
36. Manenti G, et al. Cis-acting genomic elements of the Pas1 locus control Kras mutability in lung tumors. Oncogene. 2008;27(43):5753-5758.
37. Lim K-H, Ancrile BB, Kashatus DF, Counter CM. Tumour maintenance is mediated by eNOS. Nature. 2008;452(7187):646-649.
38. Young A, Lou D, McCormick F. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 2012;3(1):112-123.
39. Jeng H-H, Taylor LJ, Bar-Sagi D. Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis. Nat Comm. 2012;3:1168.
40. Matallanas D, et al. Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol Cell. 2011;44(6):893-906.
41. Romano D, et al. The differential effects of wildtype and mutated K-Ras on MST2 signaling are determined by K-Ras activation kinetics. Mol Cell Biol. 2013;33(9):1859-1868.
42. Grabocka E, et al. Wild-type H-and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell. 2014;25(2):243-256.
43. Burd CE, et al. Mutation specific RAS oncogenic-ity explains N-RAS codon 61 selection in melanoma [published online ahead of print September 24, 2014]. Cancer Disc. doi:10.1158/2159-8290. CD-14-0729.
44. Sharp PM, Li WH. The codon adaptation index-a measure of directional synonymous codon usage bias, and its potential applications. Nucleic Acids Res. 1987;15(3):1281-1295.
45. Gu W, et al. Generalized substitution of isoencod-ing codons shortens the duration of papillomavirus L1 protein expression in transiently gene-trans-fected keratinocytes due to cell differentiation. Nucleic Acids Res. 2007;35(14):4820-4832.
46. de Rooij J, Bos JL. Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene. 1997;14(5):623-625.
47. Kashatus DF, et al. RALA and RALBP1 regulate mitochondrial fission at mitosis. Nat Cell Biol. 2011;13(9):1108-1115.
48. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Meth. 2012;9(7):671-675.
49. O'Hayer KM, Counter CM. A genetically defined normal human somatic cell system to study ras oncogenesis in vivo and in vitro. Meth Enzymol. 2006;407:637-647.
50. Schwenk F, Baron U, Rajewsky K. A cre-trans-genic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res. 1995;23(24):5080-5081.
51. O'Gorman S, Dagenais NA, Qian M, Marchuk Y. Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells. Proc Natl Acad Sci U S A. 1997;94(26):14602-14607.
52. Esteban LM, et al. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol. 2001;21(5):1444-1452.
53. Aguirre AJ, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003;17(24):3112-3126.